Yaghoubi N - Search Results

1

Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran.

Metghalchi Y, Yaghoubi N, Yousefi N, Ahmadi R, Kargar A, Zargaran M, Rezaei S. Metghalchi Y, et al. Among authors: yaghoubi n. Cost Eff Resour Alloc. 2024 Nov 13;22(1):82. doi: 10.1186/s12962-024-00592-7. Cost Eff Resour Alloc. 2024. PMID: 39538256 Free PMC article.

2

Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis.

Fatemi B, Yaghoubi N, Shobeiri N, Ahmadi R, Mousavi T, Soleymani F, Rezaei S. Fatemi B, et al. Among authors: yaghoubi n. Expert Rev Pharmacoecon Outcomes Res. 2024 Aug 11:1-10. doi: 10.1080/14737167.2024.2390041. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 39105220 Review.

3

In vitro evaluation of PLGA loaded hesperidin on colorectal cancer cell lines: an insight into nano delivery system.

Yaghoubi N, Gholamzad A, Naji T, Gholamzad M. Yaghoubi N, et al. BMC Biotechnol. 2024 Aug 2;24(1):52. doi: 10.1186/s12896-024-00882-1. BMC Biotechnol. 2024. PMID: 39095760 Free PMC article.

4

Prognostic Value of Serum MICA Levels as a Marker of Severity in COVID-19 Patients.

Farzad F, Yaghoubi N, Jabbari-Azad F, Mahmoudi M, Mohammadi M. Farzad F, et al. Among authors: yaghoubi n. Immunol Invest. 2022 Aug;51(6):1856-1866. doi: 10.1080/08820139.2022.2069035. Epub 2022 Apr 28. Immunol Invest. 2022. PMID: 35481955

5

Evaluation of antioxidant status and oxidative stress markers in HTLV-1 infected individuals: correlation with the severity of virus-induced complications.

Yaghoubi N, Youssefi M, Rafat Panah H, Jarahi L, Zahedi Avval F. Yaghoubi N, et al. J Med Microbiol. 2022 Apr;71(4). doi: 10.1099/jmm.0.001408. J Med Microbiol. 2022. PMID: 35442185

6

Total antioxidant capacity as a marker of severity of COVID-19 infection: Possible prognostic and therapeutic clinical application.

Yaghoubi N, Youssefi M, Jabbari Azad F, Farzad F, Yavari Z, Zahedi Avval F. Yaghoubi N, et al. J Med Virol. 2022 Apr;94(4):1558-1565. doi: 10.1002/jmv.27500. Epub 2021 Dec 11. J Med Virol. 2022. PMID: 34862613 Free PMC article.

7

High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker.

Yaghoubi N, Avval FZ, Khazaei M, Sahebkar A, Aghaee-Bakhtiari SH. Yaghoubi N, et al. Anticancer Agents Med Chem. 2022;22(2):206-214. doi: 10.2174/1871520621666210608094908. Anticancer Agents Med Chem. 2022. PMID: 34102990 Review.

8

MicroRNAs as potential investigative and predictive biomarkers in colorectal cancer.

Yaghoubi N, Zahedi Avval F, Khazaei M, Aghaee-Bakhtiari SH. Yaghoubi N, et al. Cell Signal. 2021 Apr;80:109910. doi: 10.1016/j.cellsig.2020.109910. Epub 2020 Dec 30. Cell Signal. 2021. PMID: 33387618 Review.

9

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.

Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. Yaghoubi N, et al. Biomed Pharmacother. 2019 Feb;110:312-318. doi: 10.1016/j.biopha.2018.11.105. Epub 2018 Dec 3. Biomed Pharmacother. 2019. PMID: 30522017 Free article. Review.

10

Thioredoxin reductase gene expression and activity among human T-cell lymphotropic virus type 1-infected patients.

Yaghoubi N, Youssefi M, Hashemy SI, Rafat Panah H, Mashkani BA, Zahedi Avval F. Yaghoubi N, et al. J Med Virol. 2019 May;91(5):865-871. doi: 10.1002/jmv.25371. Epub 2018 Dec 10. J Med Virol. 2019. PMID: 30489643

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters